EMIT II Plus Propoxyphene AssayScreen for illicit use of DARVOCET

The EMIT® II Plus Propoxyphene Assay is intended for the qualitative and semiquantitative analyses of propoxyphene in human urine at a cutoff level of 300 ng/mL.

Contact Us

Features & Benefits

Although marketed drugs such as DARVON and DARVOCET were pulled from the market by the FDA in 2011, there is still illicit use in the U.S., a situation similar to methaqualone and QUAALUDE. The EMIT® II Plus Propoxyphene Assay detects propoxyphene and propoxyphene salts, such as propoxyphene napsylate, in human urine. It also detects norpropoxyphene (N-desmethyldextropropoxyphene), the major urinary metabolite of propoxyphene.

The EMIT II Plus Propoxyphene Assay provides:

  • Excellent precision—all within-lab (total) CVs ≤1.0% or less across the assay range
  • Ready-to-use liquid reagents, calibrators, and controls
  • >98% agreement with the reference method (GC/MS)


Applications are available for the Viva-Jr®, Viva-E®, Viva-ProE®, V-Twin® drug testing systems; AU® Series analyzers; Dimension® Integrated Chemistry Systems; and Dimension Vista® Intelligent Lab Systems.


Technical Specifications

 Assay Principle

  Homogeneous Enzyme Multiplied Immonoassay (EMIT)


  300 ng/mL



 Reagent Stability

  Unopened: until expiration date. Onboard instrument: up to 4 weeks

 Calibration Frequency

  As indicated by control results